Ironwood Pharmaceuticals
IRWD
156 hedge funds and large institutions have $2.09B invested in Ironwood Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 54 increasing their positions, 44 reducing their positions, and 23 closing their positions.
191% more call options, than puts
Call options by funds: $24M | Put options by funds: $8.25M
48% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 23
35% more capital invested
Capital invested by funds: $1.55B → $2.09B (+$546M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
23% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 44
8% more funds holding
Funds holding: 145 → 156 (+11)
7.76% less ownership
Funds ownership: 127.44% → 119.69% (-7.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$27.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.1M |
| 4 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$17.2M |
| 5 |
HM
HealthCor Management
New York
|
+$9.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$29.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.9M |
| 4 |
Millennium Management
New York
|
-$6.73M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6.13M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Parallax Volatility Advisers
San Francisco,
California
| – | -$7.24K | -648 | Closed |
|
|
FANJ
177
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$5K | -597 | Closed |
|
|
MNBTD
178
Moody National Bank Trust Division
Galveston,
Texas
| – | -$4K | -500 | Closed |
|
IRWD Hedge Fund Activity: Q1 2019 in Review
156 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2019, worth a combined $2.09B — up 35% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IRWD positions and 23 closed out — a net gain of 11 holders — while 54 added to existing stakes and 44 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $27.3M. The largest seller was OrbiMed, exiting entirely with an estimated $29.8M sold.
- 156 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2019, up from 145 in Q4 2018.
- Funds reported $2.09B of Ironwood Pharmaceuticals stock for Q1 2019, up 35% quarter-over-quarter.
- 34 funds opened new Ironwood Pharmaceuticals positions in Q1 2019 and 23 closed out, a net change of +11 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2019 was Wellington Management Group, an estimated $27.3M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2019 was OrbiMed, an estimated $29.8M sold.
Based on aggregated 13F filings for Q1 2019.